The discussions certainly continue. A post by Dr. Michael Levy, a member of the Medical and Scientific Council of the TMA, and an Assistant Professor of Neurology at Johns Hopkins University (http://myelitis.org/resources/tma-blog/research-studies/stem-cells-in-transverse-myelitis-are-we-ready/) on 14th February 2014, was very technical, and did not answer the question: "Are we ready?"
Conversely, another site: "Stem Cell Regen Med" (http://www.stemcellregenmed.com/Transverse_Myelitis.html) has clinics in Florida and Peru, and their front page seems to be very upbeat, as though the research is already completed, and overwhelmingly positive:
"Transverse myeltis is a condition that results in the inflammation of the myelin sheath of the spinal cord. The area targeted goes across the width of the spinal cord at a certain level of the spinal cord. The problem occurs after vaccines (DPT, Influenza, viral infections, post radiation treatments, etc.). The underlying problem is that certain elements of the patient’s own immune system cause inflammation and sometimes destruction of the myelin.
- -> Autologous stem cells. The patient is given an injection of G-CSF once daily for three days. Peripheral blood or a bone marrow aspirate is withdrawn and in the laboratory, autologous stem cells are extracted and administered to the patient.
- -> Following the above administration, the patient is given via spinal canal administration at the level of disease, neuron stem cells mixed with neurotrophins, nerve cell factor, neuropeptide protein, and glial derived neurotrophins oligodendrocytes. In addition, the following may be given: riluzole that targets sodium dysregulation in the affected spinal cord, minocycline that targets apoptosis, and neuroinflammation.
- -> Targeting immune factors include anti-IL-6, anti-TNF, IL-17 and IL-1beta which attack the myelin in this condition.
- -> Targeting axonal inhibitors such as Rho with Cethrin and ATI-355 against Nogo.
- -> Electric field stimulation."